| Rx0000463 |
GE Healthcare, Inc. |
03/31/2023 |
00407141509 |
OMNIPAQUE ORAL SOLUTION 10 BOTTLE 500 ML 4500 MG |
Brand |
FDA |
01/01/2023 |
21.00 |
101.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000463 |
GE Healthcare, Inc. |
03/31/2023 |
00407141612 |
OMNIPAQUE ORAL SOLUTION 10 BOTTLE 500 ML 6000 MG |
Brand |
FDA |
01/01/2023 |
22.50 |
105.00 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000437 |
Genus Lifesciences Inc. |
09/30/2023 |
64950034316 |
Hydrocodone with Acetaminophen oral solution, 7.5mg and 325mg per 15mL, 473 mL bottle |
Generic |
FDA |
09/08/2023 |
159.00 |
195.00 |
None |
Non-innovator Multiple Source Drug |
20000 |
None |
Increased state licensing cost, increased manufacturing costs, increased materials and components costs |
None |
we're working with suppliers to try to reduce costs, and improve batch efficiencies |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958250501 |
BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide), Tablet, 30/120/15 mg, 30 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
211.44 |
3795.24 |
11/08/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958250103 |
BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide), Tablet, 50/200/25 mg, 30 ct, US, Blister Pack |
Brand |
FDA |
01/01/2023 |
211.44 |
3795.24 |
11/08/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958250101 |
BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide), Tablet, 50/200/25 mg, 30 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
211.44 |
3795.24 |
11/08/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958090101 |
CAYSTON (aztreonam), Sterile Liquid for Inhalation, 75 mg/vial, 84 Vials, US, 28 Day Kit |
Brand |
FDA |
01/01/2023 |
1029.00 |
11423.16 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958110101 |
COMPLERA (emtricitabine, rilpivirine, tenofovir disoproxil fumarate), Tablet, 200/25/300 mg, 30 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
192.43 |
3453.96 |
01/14/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958200202 |
DESCOVY (emtricitabine and tenofovir alafenamide), Tablet, 200/25 mg, 30 ct, US, Blister Pack |
Brand |
FDA |
01/01/2023 |
120.29 |
2159.12 |
02/15/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958200201 |
DESCOVY (emtricitabine and tenofovir alafenamide), Tablet, 200/25 mg, 30 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
120.29 |
2159.12 |
02/15/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958190101 |
GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), Tablet,150/150/200/10mg,30ct,US,Bottle |
Brand |
FDA |
01/01/2023 |
211.44 |
3795.24 |
04/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958080205 |
LETAIRIS (ambrisentan), Tablet, 10 mg, 10 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
371.56 |
4124.72 |
10/14/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958080201 |
LETAIRIS (ambrisentan), Tablet, 10 mg, 30 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
1114.69 |
12374.23 |
10/14/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958080105 |
LETAIRIS (ambrisentan), Tablet, 5 mg, 10 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
371.56 |
4124.72 |
10/14/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958080101 |
LETAIRIS (ambrisentan), Tablet, 5 mg, 30 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
1114.69 |
12374.23 |
10/14/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958210101 |
ODEFSEY (emtricitabine, rilpivirine, and tenofovir alafenamide), Tablet, 200/25/25 mg, 30 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
192.43 |
3453.96 |
02/15/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958120101 |
STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), Tablet, 150/150/200/300 mg, 30 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
221.81 |
3981.22 |
04/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958140101 |
TYBOST (cobicistat), Tablet,150mg,30ct,US,Bottle |
Brand |
FDA |
01/01/2023 |
15.78 |
283.30 |
04/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958230101 |
VEMLIDY (tenofovir alafenamide), Tablet, 25 mg, 30 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
76.56 |
1374.25 |
02/15/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958170101 |
ZYDELIG (idelalisib), Tablet, 100 mg, 60 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
733.36 |
13163.19 |
09/02/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
03/31/2023 |
61958170201 |
ZYDELIG (idelalisib), Tablet, 150 mg, 60 ct, US, Bottle |
Brand |
FDA |
01/01/2023 |
733.36 |
13163.19 |
09/02/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000406 |
Glaukos Corporation |
03/31/2023 |
25357002503 |
PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 1 Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. Please see complete product description in general comments. |
Brand |
FDA |
01/01/2023 |
335.00 |
3770.00 |
None |
Single Source Drug |
None |
1 |
In making the decision to increase the price of Photrexa, Glaukos considered the value in cost savings when it comes to direct medical costs as well as the improved quality of life for keratoconus patients, as compared to corneal transplantation. According to a study published in the Journal of Medical Economics in 2020, corneal cross-linking with Photrexa was found to be cost-effective within 2 years and cost-saving within 4.5 years. We also considered the value it provides to patients in terms of its durability and safety profile, and our significant investment in ongoing research and development, reimbursement and patient support programs, noting that approximately 30-35% of our revenue goes to R&D costs. |
None |
No changes or improvements caused the increase. |
None |
11/21/2019 |
Avedro, Inc. |
437751000 |
None |
Glaukos Corporation acquired all of the outstanding stock of Avedro, Inc. in a merger transaction. At the closing of the Merger each share of common stock of Avedro, Inc. issued and outstanding immediately prior to the closing was automatically cancelled and converted into the right to receive 0.365 of a share of common stock of Glaukos Corporation. No cash was exchanged. The Acquisition Cost provided in this submission is the fair value of the Glaukos stock issued in the merger transaction. |
2850.00 |
2850.00 |
2016 |
595.00 |
None |
PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 1 Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. Syringe 1 - PHOTREXA VISCOUS in a 3 mL glass syringe containing sterile 1.56 mg/mL riboflavin 5’-phosphate in 20% dextran ophthalmic solution, Syringe 2 - PHOTREXA in a 3 mL glass syringe containing sterile 1.46 mg/mL riboflavin 5’-phosphate ophthalmic solution |
| Rx0000406 |
Glaukos Corporation |
12/31/2023 |
25357002503 |
PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 1 Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. Please see complete product description in general comments. |
Brand |
FDA |
10/01/2023 |
380.00 |
4150.00 |
None |
Single Source Drug |
None |
1 |
In making the decision to increase the price of Photrexa, Glaukos considered the value in cost savings when it comes to direct medical costs as well as the improved quality of life for keratoconus patients, as compared to corneal transplantation. According to a study published in the Journal of Medical Economics in 2020, corneal cross-linking with Photrexa was found to be cost-effective within 2 years and cost-saving within 4.5 years. We also considered the value it provides to patients in terms of its durability and safety profile, and our significant investment in ongoing research and development, reimbursement and patient support programs, noting that approximately 30-35% of our revenue goes to R&D costs. |
None |
No changes or improvements caused the increase. |
None |
11/21/2019 |
Avedro, Inc. |
437751000 |
None |
Glaukos Corporation acquired all of the outstanding stock of Avedro, Inc. in a merger transaction. At the closing of the Merger each share of common stock of Avedro, Inc. issued and outstanding immediately prior to the closing was automatically cancelled and converted into the right to receive 0.365 of a share of common stock of Glaukos Corporation. No cash was exchanged. The Acquisition Cost provided in this submission is the fair value of the Glaukos stock issued in the merger transaction. |
2850.00 |
2850.00 |
2016 |
595.00 |
None |
PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 1 Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. Syringe 1 - PHOTREXA VISCOUS in a 3 mL glass syringe containing sterile 1.56 mg/mL riboflavin 5’-phosphate in 20% dextran ophthalmic solution, Syringe 2 - PHOTREXA in a 3 mL glass syringe containing sterile 1.46 mg/mL riboflavin 5’-phosphate ophthalmic solution |
| Rx0000406 |
Glaukos Corporation |
03/31/2023 |
25357002501 |
PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 10 Kits in each Box. Each Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. See complete product description in general comments. |
Brand |
FDA |
01/01/2023 |
3350.00 |
37700.00 |
None |
Single Source Drug |
0 |
1 |
This product is not offered for sale; we are working to update and correct the listing in MediSpan. |
None |
This product is not offered for sale; we are working to update and correct the listing in MediSpan. |
None |
11/21/2019 |
Avedro, Inc. |
437751000 |
None |
Glaukos Corporation acquired all of the outstanding stock of Avedro, Inc. in a merger transaction. At the closing of the Merger each share of common stock of Avedro, Inc. issued and outstanding immediately prior to the closing was automatically cancelled and converted into the right to receive 0.365 of a share of common stock of Glaukos Corporation. No cash was exchanged. The Acquisition Cost provided in this submission is the fair value of the Glaukos stock issued in the merger transaction. |
31300.00 |
31300.00 |
2016 |
5950.00 |
None |
This product is not offered for sale; we are working to update and correct the listing in MediSpan. PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 10 Kits in each Box. Each Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT 1 SYRINGE, GLASS. Syringe 1 - PHOTREXA VISCOUS in a 3 mL glass syringe containing sterile 1.56 mg/mL riboflavin 5’-phosphate in 20% dextran ophthalmic solution, Syringe 2 - PHOTREXA in a 3 mL glass syringe containing sterile 1.46 mg/mL riboflavin 5’-phosphate ophthalmic solution. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173087410 |
Arnuity Ellipta; 100 ug/1; 1 INHALER in 1 CARTON (0173-0874-10) / 30 POWDER in 1 INHALER |
Brand |
FDA |
01/01/2023 |
9.64 |
208.49 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173087414 |
Arnuity Ellipta; 100 ug/1; 1 INHALER in 1 CARTON (0173-0874-14) / 14 POWDER in 1 INHALER |
Brand |
FDA |
01/01/2023 |
4.50 |
97.29 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173087610 |
Arnuity Ellipta; 200 ug/1; 1 INHALER in 1 CARTON (0173-0876-10) / 30 POWDER in 1 INHALER |
Brand |
FDA |
01/01/2023 |
12.92 |
279.14 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173087614 |
Arnuity Ellipta; 200 ug/1; 1 INHALER in 1 CARTON (0173-0876-14) / 14 POWDER in 1 INHALER |
Brand |
FDA |
01/01/2023 |
6.02 |
130.26 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173088810 |
Arnuity Ellipta; 50 ug/1; 1 INHALER in 1 CARTON (0173-0888-10) / 30 POWDER in 1 INHALER |
Brand |
FDA |
01/01/2023 |
9.64 |
208.49 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
49401008835 |
BENLYSTA; 200 mg/mL; 4 PREFILLED AUTO-INJECTOR in 1 CARTON (49401-0088-35) > 1 mL in 1 PREFILLED AUTO-INJECTOR (49401-0088-01) |
Brand |
FDA |
01/01/2023 |
329.73 |
4611.90 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
49401008847 |
BENLYSTA; 200 mg/mL; 4 PREFILLED GLASS SYRINGE in 1 CARTON (49401-0088-47) > 1 mL in 1 PREFILLED GLASS SYRINGE (49401-0088-42) |
Brand |
FDA |
01/01/2023 |
329.73 |
4611.90 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
58160097620 |
BEXSERO 0.5ML Pre-filled Syringe; Dosage form: Injection; 10 Pack |
Brand |
FDA |
01/01/2023 |
100.27 |
2113.22 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This product was acquired by GSK in 2015 which is outside of the 5 year reporting period. Therefore, the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173059402 |
LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0594-02) / 1 KIT in 1 BLISTER PACK |
Brand |
FDA |
01/01/2023 |
56.90 |
795.83 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173075800 |
LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0758-00) / 1 KIT in 1 BLISTER PACK |
Brand |
FDA |
01/01/2023 |
35.03 |
489.99 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173075900 |
LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0759-00) / 1 KIT in 1 BLISTER PACK |
Brand |
FDA |
01/01/2023 |
100.08 |
1399.77 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173076000 |
LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0760-00) / 1 KIT in 1 BLISTER PACK |
Brand |
FDA |
01/01/2023 |
50.04 |
699.92 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173077800 |
LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0778-00) / 1 KIT in 1 BLISTER PACK |
Brand |
FDA |
01/01/2023 |
47.86 |
669.46 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173077900 |
LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0779-00) / 1 KIT in 1 BLISTER PACK |
Brand |
FDA |
01/01/2023 |
33.51 |
468.66 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173078000 |
LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0780-00) / 1 KIT in 1 BLISTER PACK |
Brand |
FDA |
01/01/2023 |
95.72 |
1338.88 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173081728 |
LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0817-28) / 1 KIT in 1 BLISTER PACK |
Brand |
FDA |
01/01/2023 |
113.79 |
1591.62 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173077602 |
LAMICTAL; 100 mg/1; 1 DOSE PACK in 1 CARTON (0173-0776-02) / 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK |
Brand |
FDA |
01/01/2023 |
32.80 |
458.81 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173064255 |
LAMICTAL; 100 mg/1; 100 TABLET in 1 BOTTLE (0173-0642-55) |
Brand |
FDA |
01/01/2023 |
129.99 |
1818.21 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173075600 |
LAMICTAL; 100 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0756-00) |
Brand |
FDA |
01/01/2023 |
64.32 |
899.69 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173064360 |
LAMICTAL; 150 mg/1; 60 TABLET in 1 BOTTLE (0173-0643-60) |
Brand |
FDA |
01/01/2023 |
85.49 |
1195.69 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173077702 |
LAMICTAL; 200 mg/1; 1 DOSE PACK in 1 CARTON (0173-0777-02) / 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK |
Brand |
FDA |
01/01/2023 |
39.14 |
547.51 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173075700 |
LAMICTAL; 200 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0757-00) |
Brand |
FDA |
01/01/2023 |
68.59 |
959.40 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173064460 |
LAMICTAL; 200 mg/1; 60 TABLET in 1 BOTTLE (0173-0644-60) |
Brand |
FDA |
01/01/2023 |
93.06 |
1301.63 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173077202 |
LAMICTAL; 25 mg/1; 1 DOSE PACK in 1 CARTON (0173-0772-02) / 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK |
Brand |
FDA |
01/01/2023 |
28.72 |
401.73 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173063302 |
LAMICTAL; 25 mg/1; 100 TABLET in 1 BOTTLE (0173-0633-02) |
Brand |
FDA |
01/01/2023 |
113.80 |
1591.78 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173052700 |
LAMICTAL; 25 mg/1; 100 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0527-00) |
Brand |
FDA |
01/01/2023 |
118.21 |
1653.45 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173075400 |
LAMICTAL; 25 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0754-00) |
Brand |
FDA |
01/01/2023 |
30.03 |
420.01 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173063310 |
LAMICTAL; 25 mg/1; 35 TABLET in 1 DOSE PACK (0173-0633-10) |
Brand |
FDA |
01/01/2023 |
39.83 |
557.14 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173078100 |
LAMICTAL; 250 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0781-00) |
Brand |
FDA |
01/01/2023 |
93.54 |
1308.32 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173076100 |
LAMICTAL; 300 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0761-00) |
Brand |
FDA |
01/01/2023 |
102.89 |
1439.14 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173052600 |
LAMICTAL; 5 mg/1; 100 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0526-00) |
Brand |
FDA |
01/01/2023 |
110.12 |
1540.21 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173077402 |
LAMICTAL; 50 mg/1; 1 DOSE PACK in 1 CARTON (0173-0774-02) / 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK |
Brand |
FDA |
01/01/2023 |
30.76 |
430.30 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173075500 |
LAMICTAL; 50 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0755-00) |
Brand |
FDA |
01/01/2023 |
60.05 |
839.92 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173089201 |
Nucala; 100 mg/mL; 1 SYRINGE in 1 CARTON (0173-0892-01) / 1 mL in 1 SYRINGE |
Brand |
FDA |
01/01/2023 |
256.05 |
3581.39 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
00173089242 |
Nucala; 100 mg/mL; 1 SYRINGE in 1 CARTON (0173-0892-42) / 1 mL in 1 SYRINGE |
Brand |
FDA |
01/01/2023 |
256.05 |
3581.39 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
58160081912 |
SHINGRIX 0.5mL Vial; Dosage form: Injection; 1 Pack |
Brand |
FDA |
01/01/2023 |
11.84 |
183.41 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
58160082311 |
SHINGRIX 0.5mL Vial; Dosage form: Injection; 10 Pack |
Brand |
FDA |
01/01/2023 |
118.38 |
1834.06 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2023 |
69656010330 |
ZEJULA 100 mg 30 CAPSULE in 1 BOTTLE |
Brand |
FDA |
01/01/2023 |
489.32 |
8644.65 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
01/22/2019 |
TESARO, INC |
None |
1 |
None |
6584.00 |
None |
2018 |
6584.00 |
None |
Note on Acquisition Fields ACQUIRED_FROM_COMPANY: GSK acquired Zejula as a part of its overall acquisition of TESARO Inc, the company that developed Zejula, and there was no specific acquisition of Zejula itself ACQUISITION_PRICE: GSK acquired Zejula as a part of its overall acquisition of TESARO Inc, the company that developed Zejula, and there was no specific acquisition of Zejula itself WAC_YEAR_PRIOR_TO_ACQ: Zejula did not have a WAC one year prior to acquisition as it was not yet approved at that time |